HomeInsightsStock Comparison

Bliss Gvs Pharma Ltd vs Laurus Labs Ltd Stock Comparison

Bliss Gvs Pharma Ltd vs Laurus Labs Ltd Stock Comparison

Last Updated on: Apr 28, 2025

Key Highlights

  • The Latest Trading Price of Bliss GVS Pharma Ltd is ₹ 120.85 as of 28 Apr 09:33.
  • The P/E Ratio of Bliss GVS Pharma Ltd changed from 10.7 on March 2020 to 15.6 on March 2024 . This represents a CAGR of 7.83% over 5 yearsThe P/E Ratio of Laurus Labs Ltd changed from 13.5 on March 2020 to 131.5 on March 2024 . This represents a CAGR of 57.66% over 5 years.
  • The Market Cap of Bliss GVS Pharma Ltd changed from ₹ 1039 crore on March 2020 to ₹ 1179 crore on March 2024 . This represents a CAGR of 2.55% over 5 yearsThe Market Cap of Laurus Labs Ltd changed from ₹ 3449 crore on March 2020 to ₹ 21113 crore on March 2024 . This represents a CAGR of 43.67% over 5 years.
  • The revenue of Bliss GVS Pharma Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 revenue of ₹ 225.68 crore. This represent the decline of -100% The revenue of Laurus Labs Ltd for the Mar '25 is ₹ 1778 crore as compare to the Dec '24 revenue of ₹ 1424 crore. This represent the growth of 24.88%.
  • The ebitda of Bliss GVS Pharma Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 ebitda of ₹ 45.05 crore. This represent the decline of -100% The ebitda of Laurus Labs Ltd for the Mar '25 is ₹ 479.17 crore as compare to the Dec '24 ebitda of ₹ 294.57 crore. This represent the growth of 62.67%.
  • The net profit of Bliss GVS Pharma Ltd changed from ₹ 14.37 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The net profit of Laurus Labs Ltd changed from ₹ 28.4 crore to ₹ 233.87 crore over 8 quarters. This represents a CAGR of 186.96% .
  • The Dividend Payout of Bliss GVS Pharma Ltd changed from 5.58 % on March 2020 to 10.34 % on March 2024 . This represents a CAGR of 13.13% over 5 yearsThe Dividend Payout of Laurus Labs Ltd changed from 10.13 % on March 2020 to 19.27 % on March 2024 . This represents a CAGR of 13.72% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Bliss GVS Pharma Ltd

  • Bliss GVS Pharma Limited was originally incorporated as a Private Limited Company in the name of Bliss Chemicals & Pharmaceuticals India Private Limited in 1984.
  • The status converted into a Public Limited Company and the name of the Company was changed to Bliss Chemicals & Pharmaceuticals India Limited and further to Bliss GVS Pharma Limited on May 12, 2006. The Company, founded in 1984 with the objective of ensuring healthcare access worldwide, is one of the pharmaceutical industries' fastest-growing businesses.
  • The Company has a robust portfolio of more than 250 products and is a global leader in the dosage forms for suppositories and pessaries.
  • It has a strong foothold in Sub Saharan Africa.
  • The Company is engaged in manufacturing, marketing, trading and export of pharmaceutical products.

About Laurus Labs Ltd

  • Laurus Labs is a science-led, fully integrated pharmaceutical and biotechnology manufacturing company with a leadership position in generic active pharmaceutical ingredients (APIs) in selected high-growth therapeutic areas of anti-retrovirals (ARVs), Hepatitis C and Oncology.
  • The company also manufactures APIs in oncology and other therapeutic areas, such as anti-asthma, ophthalmology, antidiabetics, cardiovascular, proton pump inhibitors (PPIs) amongst others.
  • The company currently operates 4 manufacturing facilities in Visakhapatnam, Andhra Pradesh.
  • Three of these facilities manufacture APIs and ingredients, while the fourth facility produces Finished Dosage Formulations (FDFs) and one API. The company's strategic and early investments in R&D and manufacturing infrastructure has enabled it to become one of the leading suppliers of APIs in the ARV therapeutic area to multi-national pharmaceutical formulation companies which cater to the large and fast-growing 'donor-funded access-to-medicines markets' of Sub-Saharan Africa, South-East Asia and Latin America.

Bliss GVS Pharma Ltd News Hub

News

Bliss GVS Pharma schedules board meeting

Bliss GVS Pharma will hold a meeting of the Board of Directors of the Company on 28 Januar...

Read more

22 Jan 2025 09:41

News

Bliss GVS Pharma allots 34,250 equity shares under ESOP

Bliss GVS Pharma has allotted 34,250 equity shares under ESOP on 06 December 2024. With th...

Read more

06 Dec 2024 19:02

News

Bliss GVS Pharma soars after manufacturing units get GMP certificate from Romania medical authority

In a regulatory filing made on Saturday, the company informed that its manufacturing facil...

Read more

25 Nov 2024 09:40

News

Bliss GVS Pharma's manufacturing facilities complete EU GMP inspection

Bliss GVS Pharma announced that the company's manufacturing facility situated at Plot No. ...

Read more

23 Nov 2024 15:02

News

Bliss GVS Pharma to table results

Bliss GVS Pharma will hold a meeting of the Board of Directors of the Company on 24 Octobe...

Read more

18 Oct 2024 10:48

News

Bliss GVS Pharma allots 1.57 lakh equity shares under ESOP

Bliss GVS Pharma has allotted 157,550 equity shares under ESOP on 04 October 2024. With th...

Read more

04 Oct 2024 18:37

Laurus Labs Ltd News Hub

News

Board of Laurus Labs recommends 2nd interim dividend

Laurus Labs announced that the Board of Directors of the Company at its meeting held on 24...

Read more

24 Apr 2025 16:52

News

Laurus Lab Q4 PAT soars to Rs 234 cr

Revenue from operations jumped 19.49% YoY to Rs 1,720.30 crore in Q4 FY25. Profit before t...

Read more

24 Apr 2025 17:20

News

Laurus Labs declare Quarterly Result

Laurus Labs will hold a meeting of the Board of Directors of the Company on 24 April 2025....

Read more

11 Apr 2025 09:55

News

Laurus Labs to acquire 26% stakes in Kurnool Renewables for Rs 35 cr

The strategic move will enable Laurus Labs to access 25.53 MW of renewable wind and solar ...

Read more

28 Mar 2025 15:15

News

Board of Laurus Labs approves investment of Rs 83.30 cr in KRKA Pharma

The Board of Laurus Labs at its meeting held on 06 March 2025 has approved investment of a...

Read more

06 Mar 2025 19:44

News

Laurus Labs Ltd soars 3.43%, up for third straight session

Laurus Labs Ltd rose for a third straight session today. The stock is quoting at Rs 564.2,...

Read more

05 Mar 2025 13:06

SWOT Analysis Of Laurus Labs Ltd

Strength

6

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Bliss GVS Pharma Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Laurus Labs Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Bliss GVS Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Bliss GVS Pharma Ltd and Laurus Labs Ltd

Which company has a larger market capitalization, Bliss GVS Pharma Ltd or Laurus Labs Ltd?

Market cap of Bliss GVS Pharma Ltd is 1,286 Cr while Market cap of Laurus Labs Ltd is 33,724 Cr

What are the key factors driving the stock performance of Bliss GVS Pharma Ltd and Laurus Labs Ltd?

The stock performance of Bliss GVS Pharma Ltd and Laurus Labs Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bliss GVS Pharma Ltd and Laurus Labs Ltd?

As of April 28, 2025, the Bliss GVS Pharma Ltd stock price is INR ₹122.05. On the other hand, Laurus Labs Ltd stock price is INR ₹625.4.

How do dividend payouts of Bliss GVS Pharma Ltd and Laurus Labs Ltd compare?

To compare the dividend payouts of Bliss GVS Pharma Ltd and Laurus Labs Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions